Industry News Tablet Release Reinvented: Robotics, Vision, and Spectral Intelligence   Lilly’s eloralintide demonstrates meaningful weight loss and favorable tolerability in adults with obesity Pfizer response to Delaware chancery court ruling Eli Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans   Roche’s Gazyva/Gazyvaro shows significant reduction in disease activity for systemic lupus erythematosus Gilead’s Livdelzi highlights sustained efficacy in primary biliary cholangitis offering alkaline phosphatase reduction and potential to slow disease progression Astrazeneca’s Baxdrostat highlights significant placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial Moderna’s first patient in phase 1/2 study of investigational T-cell engager for multiple myeloma   Dupixent reduces signs and symptoms of allergic fungal rhinosinusitis Potency Assays and Functional Characterisation – Going Hand-in-Hand during Product Development up to Commercial Licensing Roche’s fenebrutinib highlights positive phase III results as the only BTK inhibitor in both relapsing and primary progressive multiple sclerosis Gilead’s phase 3 ASCENT-07 study update Upcoming Webinars